Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Treatment for Acute Myeloid Leukemia
Typical Dosage: Varies by preparative regimen and stem cell source
Effectiveness
90%
Safety Score
20%
Clinical Trials
100
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
20
DangerousModerateSafe
Treatment Details
Dosage Range
Varies by preparative regimen and stem cell source
Time to Effect
6-12 months for full immune recovery
Treatment Duration
Initial hospitalization 1-2 months, intensive outpatient 6-12 months, lifetime follow-up
Evidence Quality
HIGHNumber Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$500,000
Side Effect Mgmt:$150,000
Total Annual:$700,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
6
Outcome-Based Costs
Cost per Remission
$1,400,000
Comparison vs Intensive Chemotherapy
Cost Difference
+$500,000/year
More expensive
QALY Difference
+3.00 QALYs
Better outcomes
Dominance
No dominance
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes
for Acute Myeloid Leukemia
Active Clinical Trials
15 active trials recruiting for Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) in Acute Myeloid Leukemia
The Efficacy of Allo-HSCT in ND HR-CBF-AML
NCT06458244RECRUITING
90 participants
OBSERVATIONAL
Shanghai, China
Started: Sep 21, 2024
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT06571825RECRUITINGPHASE4
118 participants
INTERVENTIONAL
Hangzhou, China
Started: Jul 17, 2024
A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia
NCT04822766ACTIVE NOT RECRUITINGNA
24 participants
INTERVENTIONAL
Paris, France
Started: Dec 31, 2021
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974RECRUITINGPHASE2
300 participants
INTERVENTIONAL
Minneapolis, United States
Started: Mar 30, 2018
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
NCT06903702RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Jun 4, 2025
MRD Response-adapted Allo-HSCT for Adverse-risk AML
NCT06301425RECRUITINGNA
178 participants
INTERVENTIONAL
Beijing, China
Started: May 24, 2024
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
NCT05858814RECRUITINGPHASE1, PHASE2
72 participants
INTERVENTIONAL
Hefei, China
Started: May 4, 2023
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
NCT05772273RECRUITINGNA
43 participants
INTERVENTIONAL
Suzhou, China
Started: Mar 15, 2023
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
NCT05682755RECRUITINGPHASE1, PHASE2
77 participants
INTERVENTIONAL
Chengdu, China
Started: Dec 22, 2022
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NCT06232694RECRUITINGNA
54 participants
INTERVENTIONAL
Nanjing, China
Started: Jan 1, 2024
CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia
NCT07201727NOT YET RECRUITINGEARLY_PHASE1
10 participants
INTERVENTIONAL
Started: Sep 30, 2025
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
NCT06765928NOT YET RECRUITINGPHASE2
73 participants
INTERVENTIONAL
Shanghai, China
Started: Jan 1, 2025
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
NCT07126782RECRUITINGEARLY_PHASE1
10 participants
INTERVENTIONAL
Beijing, China
Started: Jul 20, 2025
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
NCT07183878RECRUITINGNA
138 participants
INTERVENTIONAL
Hangzhou, China
Started: Aug 20, 2025
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
NCT06385808NOT YET RECRUITINGNA
37 participants
INTERVENTIONAL
Started: May 1, 2024
Completed Clinical Trials
1 completed trial for Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) in Acute Myeloid Leukemia
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
NCT02487069COMPLETEDNA
876 participants
INTERVENTIONAL
Guangzhou, China
Started: Jun 1, 2015
Showing 20 of 101 total trials